CRIS, Curis (formerly CBMI) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CRIS, Curis (formerly CBMI)

CRIS 1.309

-8.5%

Nov 7 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: John McCarthy	12/6/2004 12:26:35 PM
	of 668

2004 - [Business Week][Rich Suitors May Come Courting Curis] INSIDE WALL STREET By Gene G. Marcial Rich Suitors May Come Courting Curis With three big pharmas -- Genentech (DNA ), Johnson & Johnson (JNJ ), and Wyeth (WYE ) -- as its partners, tiny Curis (CRIS ) is a "sitting duck" for a takeover as it develops drugs to combat a number of diseases. So say some investors who own shares but don't want to be named. They note that Curis' market cap is just $200 million. One hedge-fund manager puts Curis' buyout value at 9 a share, or $423 million. Its technology uses proteins or small molecules to modulate "regulatory pathways" that control the repair and regeneration of tissues and organs. Curis has come up with drugs aimed at basal cell carcinoma, with Genentech as its partner; kidney diseases, with J&J; and cardiovascular and neurological ills, with Wyeth. yahoo.businessweek.com I'm not in this but thought I'd pass it on ... John McCarthy

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next